Review
Medicine, Research & Experimental
Wen-Hung Wang, Aspiro Nayim Urbina, Chih-Yen Lin, Zih-Syuan Yang, Wanchai Assavalapsakul, Arunee Thitithanyanont, Po-Liang Lu, Yen-Hsu Chen, Sheng-Fan Wang
Summary: The development of dengue vaccines is crucial in preventing and controlling the global health threat caused by Dengue virus. Current approved vaccines have demonstrated low efficacy in certain populations, leading to ongoing investigation and development of novel strategies for dengue vaccines.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Review
Immunology
Paul Kato Kitandwe, Paul F. McKay, Pontiano Kaleebu, Robin J. Shattock
Summary: RVF is a mosquito-borne viral zoonosis that causes harm to both humans and animals. There is a need for more safe and effective DIVA-compatible vaccines due to limitations of the currently available RVF vaccines.
Article
Chemistry, Analytical
Pei-Shan Tsai, Pin-Xian Du, Batuhan Birol Keskin, Nan-Yao Lee, Shu-Wen Wan, Ya-Lan Lin, Wen-Yu Su, Pei-Chun Lin, Wei-Hsun Lin, Hsi-Chang Shih, Tzong-Shiann Ho, Guan-Da Syu
Summary: This study aims to analyze the humoral immunity and cross-reactivity in dengue patients using a multiplexed protein microarray. The results show that patients with severe dengue have higher levels of IgG antibodies against multiple Flavivirus antigens. Logistic regression analysis identifies groups of markers that can effectively distinguish dengue patients from healthy controls and hospitalized patients from mild cases.
ANALYTICAL CHEMISTRY
(2023)
Review
Immunology
Vincent Dussupt, Kayvon Modjarrad, Shelly J. Krebs
Summary: The unprecedented Zika outbreak in the Americas from 2015-2016 led to global concern and accelerated the deployment of vaccine and therapeutic countermeasures. Several potent neutralizing antibodies against Zika and related flaviviruses have been discovered in recent years. Structure-based approaches have helped identify species-specific and cross-protective epitopes with therapeutic value.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Multidisciplinary Sciences
Hoa Thi My Vo, Vinit Upasani, Heidi Auerswald, Sokchea Lay, Sotheary Sann, Axelle Vanderlinden, Sreymom Ken, Sopheak Sorn, Sowath Ly, Veasna Duong, Philippe Dussart, Tineke Cantaert
Summary: Heterotypic secondary dengue virus (DENV) infection increases the risk of severe disease. Antibody levels against the infecting serotype peak at 10 days after infection and remain stable for 60 days. Secondary infected patients have higher antibody levels and functional antibody response compared to primary infected patients.
SCIENTIFIC REPORTS
(2022)
Review
Immunology
Jue Hou, Weijian Ye, Jianzhu Chen
Summary: Dengue is a common mosquito-borne disease caused by four closely related viruses. Developing a vaccine that can protect against all four virus strains without adverse effects is a challenge. Several tetravalent live attenuated vaccine candidates have entered clinical trials.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Microbiology
Mercedes Viettri, Gerson Caraballo, Maria Elena Sanchez, Aurora Espejel-Nunez, Abigail Betanzos, Vianney Ortiz-Navarrete, Guadalupe Estrada-Gutierrez, Porfirio Nava, Juan E. Ludert
Summary: This study compared the growth and dissemination of Zika virus (ZIKV) with dengue virus (DENV) and yellow fever virus (YFV-17D) in cells. The results showed that ZIKV has a greater ability to infect cells and inhibits the immune and chemical responses of cells.
MICROBIOLOGY SPECTRUM
(2023)
Article
Medicine, General & Internal
Ralph Huits, Kristina M. Angelo, Bhawana Amatya, Sapha Barkati, Elizabeth D. Barnett, Emmanuel Bottieau, Hannah Emetulu, Loic Epelboin, Gilles Eperon, Line Medebb, Federico Gobbi, Martin P. Grobusch, Oula Itani, Sabine Jordan, Paul Kelly, Karin Leder, Marta Diaz-Menendez, Nobumasa Okumura, Aisha Rizwan, Camilla Rothe, Mauro Saio, Jesse Waggoner, Yukihiro Yoshimura, Michael Libman, Davidson H. Hamer, Eli Schwartz
Summary: This study retrospectively analyzed the cases of severe dengue or dengue with warning signs among international travelers reported to GeoSentinel from 2007 to 2022. The incidence of complicated dengue was relatively low in travelers. Clinicians should closely monitor patients with dengue for warning signs of severe disease.
ANNALS OF INTERNAL MEDICINE
(2023)
Article
Virology
Clayton J. Wollner, Michelle Richner, Mariah A. Hassert, Amelia K. Pinto, James D. Brien, Justin M. Richner
Summary: Dengue virus is a common vector-borne viral disease with nearly 400 million infections worldwide annually. Vaccination with a novel mRNA vaccine encoding DENV1 structural proteins induced neutralizing antibody and cellular immune responses, effectively protecting against a lethal DENV challenge. The vaccine provided serotype-specific immunity and reduced antibody-dependent enhancement compared to live viral infection, highlighting its potential as an effective dengue vaccine.
JOURNAL OF VIROLOGY
(2021)
Review
Infectious Diseases
Chung-Hao Huang, Yu-Te Tsai, Seng-Fan Wang, Wen-Hung Wang, Yen-Hsu Chen
Summary: Development of efficient dengue vaccines is still lacking despite the presence of licensed vaccines like CYD-TDV. Efforts are being made to improve vaccine efficacy and eliminate the risk of severe dengue through heterologous prime-boost regimens. Additionally, the absence of an ideal animal model remains a challenge in dengue vaccine development.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
(2021)
Article
Medicine, Research & Experimental
Ruixue Hou, Lewis E. Tomalin, Jessica Pintado Silva, Seunghee Kim-Schulze, Stephen S. Whitehead, Ana Fernandez-Sesma, Anna P. Durbin, Mayte Suarez-Farinas
Summary: Understanding the immune response to dengue virus is crucial for dengue vaccine development. This study showed that the tetravalent vaccine has better protective effects against DENV compared to the trivalent admixture. Additionally, differences in immune responses between Black and White participants were observed.
Article
Public, Environmental & Occupational Health
Lina Tian, Chumin Liang, Xiaorong Huang, Zhe Liu, Juan Su, Chuan Guo, Guanghu Zhu, Jiufeng Sun
Summary: In this study, the genomic epidemiology of a dengue outbreak in Shantou, China in 2019 was investigated using whole-genome sequencing. The outbreak lasted from July to December, with a total of 944 confirmed cases and no gender bias or fatalities. Multiple introductions and internal transmission were observed, highlighting the importance of genomic epidemiology in real-time monitoring of disease outbreaks.
FRONTIERS IN PUBLIC HEALTH
(2023)
Review
Immunology
Gregorie Lebeau, Alise Lagrave, Eva Ogire, Lauriane Grondin, Soundary Seriacaroupin, Cedric Moutoussamy, Patrick Mavingui, Jean-Jacques Hoarau, Marjolaine Roche, Pascale Krejbich-Trotot, Philippe Despres, Wildriss Viranaicken
Summary: Dengue, a global public health issue caused by four genetically related but antigenically distinct serotypes, can range from mild symptoms to severe dengue with plasma leakage and bleeding. Research has shown that the secreted soluble hexameric form of DENV nonstructural protein-1 (sNS1) plays a significant role in the pathogenesis of severe dengue. Further understanding of sNS1 may lead to improved vaccine efficiency against severe dengue.
Article
Pediatrics
Joshua M. Wong, Laura E. Adams, Anna P. Durbin, Jorge L. Munoz-Jordan, Katherine A. Poehling, Liliana M. Sanchez-Gonzalez, Hannah R. Volkman, Gabriela Paz-Bailey
Summary: Dengue is a common arboviral disease caused by dengue viruses, with the greatest burden in tropical and sub-tropical regions. Effective prevention and control measures are necessary to prevent the increasing disease burden and geographic range. Clinicians should understand the clinical presentation and management of dengue patients. The recommendation of Dengvaxia as a routine vaccine and the requirement for laboratory testing of potential recipients are important milestones in controlling dengue.
Article
Immunology
Isamu Tsuji, David Dominguez, Michael A. Egan, Hansi J. Dean
Summary: A novel avidity assay using biolayer interferometry and dengue virus-like particles was developed to assess antibody affinity maturation. Vaccination with tetravalent dengue vaccine candidate (TAK-003) increased avidity index, which remained high throughout 1 year postvaccination.
JOURNAL OF INFECTIOUS DISEASES
(2022)